MOLECULAR PARTNERS AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.485 CHF | -2.52% |
|
0.00% | -0.15% |
| Mar. 15 | Transcript : Molecular Partners AG, 2023 Earnings Call, Mar 15, 2024 | |
| Mar. 15 | Molecular Partners Swings to Loss in FY23; Revenue Down | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Calendar
2024-04-17
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.575
CHF
Average target price
9.5
CHF
Spread / Average Target
+165.73%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -0.15% | 129M | |
| -2.34% | 103B | |
| +2.31% | 96.56B | |
| +0.61% | 22.61B | |
| -16.72% | 21.18B | |
| -3.11% | 19.07B | |
| -41.75% | 16.53B | |
| -23.26% | 14.46B | |
| -0.02% | 13.25B | |
| +22.69% | 11.1B |
- Stock Market
- Equities
- MOLN Stock
- News Molecular Partners AG
- Molecular Partners : Gets US FDA Fast Track Designation For Ensovibep in COVID-19 Treatment
